FDA D.I.S.C.O. Burst Edition: FDA approval of ABECMA (idecabtagene vicleucel) the first FDA appro...

(3:31)

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma

(5:31)

FDA D.I.S.C.O. Burst Edition: FDA approval of Trodelvy (sacituzumab govitecan-hziy) for HR-positi...

(4:1econd)

FDA D.I.S.C.O. Burst Edition: FDA approval of Omisirge (omidubicel-onlv) to reduce time to neutro...

(3:31)

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

(6:1econd)

FDA D.I.S.C.O.: A new drug approval for IDH1 positive relapsed or refractory Acute Myeloid Leukemia

(6:31)

FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adul...

(3:1econd)

FDA D.I.S.C.O. Burst Edition: FDA approval of Imfinzi (durvalumab) for adult patients with locall...

(3:31)

Understand the Applicability of FDA’s Computer Software Assurance Guidance to Data Integrity

(1:6:45)

Navigating FDA's Drug Information Resources

(50:52)

African Swine Fever: Bioassets

(23:24)

An Overview of FDA's Project Facilitate Oncology Expanded Access Program

(50:9)

Congressional Hearing with the FDA

(9:52)

FDA D.I.S.C.O. Burst Edition: FDA approval of Ojemda (tovorafenib) for relapsed or refractory ped...

(4:1econd)

FDA Drug Topics - FDA Drug Information Resources and Applicability to Health Care Professionals

(52:15)

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced ...

(3:31)

FDA Oncology Drug Development Overview – Past to Present

(29:20)

IFA Wartburg - The free German youth / IFA Wartburg - Freie Deutsche Jugend (FDJ)

(4:37)

After 25 years at FDA, Richard Pazdur reflects on opportunities for change at the agency

(1:1:33)

FDA D.I.S.C.O. Burst Edition: FDA approvals of Rituxan (rituximab) plus chemotherapy for pediatri...

(7:1econd)

FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma

(6:31)

FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur

(3:21)

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for patients with metastat...

(3:31)

FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednison...

(3:31)

FDA D.I.S.C.O.: First FDA approval of a CAR T-cell immunotherapy

(6:1econd)

FDA D.I.S.C.O.: FDA approval of larotrectinib for advanced malignancies with NTRK gene fusion

(7:31)

FDA D.I.S.C.O.: A new drug approval for non-metastatic castration-resistant prostate cancer

(5:1econd)

FDA D.I.S.C.O.: FDA approval of Cablivi for acquired thrombotic thrombocytopenic purpura

(8:1econd)

FDA D.I.S.C.O.: FDA approval of moxetumomab pasudotox-tdfk for relapsed or refractory hairy cell ...

(6:31)

FDA D.I.S.C.O. Burst Edition: FDA approval of Fruzaqla (fruquintinib) for adult patients with met...

(3:31)